MARLBOROUGH, Mass.,
Oct. 24, 2016 /PRNewswire/ -- Boston
Scientific (NYSE: BSX) today announced key data which will be
presented at the 28th Transcatheter Cardiovascular Therapeutics
(TCT), the annual scientific symposium of the Cardiovascular
Research Foundation, in Washington,
D.C., on October 29 –
November 2.
Notably, WATCHMAN™ Left Atrial Appendage Closure (LAAC) Device
data will be featured in a late-breaking clinical trial session on
Wednesday, November 2, and will
highlight the procedural safety of the device since it became
commercially available in the U.S. in March
2015. Additionally, the PLATINUM Diversity trial which
examined acute procedural performance with the Promus PREMIER™
Everolimus-Eluting Stent in women and minorities – historically
underrepresented patient populations in clinical trials – will be
presented at the first report investigation session on Tuesday, November 1.
Other oral presentations of interest include PREVAIL three-year
and PROTECT AF five-year follow-up data related to long-term event
rates for LAA closure with the WATCHMAN device and three-year
outcomes of the Lotus™ Valve System in high-risk patients with
severe aortic stenosis.
"Over the course of my thirty-year career as an interventional
cardiologist and chief medical officer, there has been a
renaissance in the treatment of heart disease – with a surging
reliance on minimally-invasive devices to deliver the outcomes
previously achieved with surgery," said Keith Dawkins, M.D., global chief medical
officer, Boston Scientific. "In addition to enhancing the
established body of clinical evidence for our products which treat
coronary and peripheral artery disease, this meeting will
demonstrate the exceptional advancement of our Structural Heart
portfolio – comprised of the Lotus Valve System for transcatheter
aortic valve replacement, and the WATCHMAN device, the only
FDA-approved LAAC device."
ORAL ABSTRACTS OF INTEREST (listed
chronologically)
Monday, October 31
Oral Abstract Sessions
- WATCHMAN LAAC Device: Long-Term Event Rates for Left
Atrial Appendage Closure with WATCHMAN: PROTECT AF Five-Year and
PREVAIL Three-Year Follow-up: Vivek
Reddy, M.D., will present at 12:15
PM in Room 203, Level 2.
- Lotus Valve System: Three-Year Outcomes With the Fully
Repositionable and Retrievable Lotus Transcatheter Aortic
Replacement Valve in 120 High-Risk Surgical Patients With Severe
Aortic Stenosis: Results From the REPRISE II CE-Mark Study:
Professor Ian Meredith will present
at 12:30 PM in Room 203, Level
2.
Tuesday, November 1
First Report Investigation
- PLATINUM DIVERSITY: Outcomes from a Large-Scale,
Prospective Registry of Coronary Artery Stent Implantation in Women
and Minorities: Wayne B. Batchelor,
M.D., will present at 12:45 PM in the
Ballroom, Level 3.
Wednesday, November 2
Late-Breaking Clinical Trial
- WATCHMAN LAAC Device: Post-FDA Approval, Initial US
Clinical Experience with Watchman Left Atrial Appendage Closure for
Stroke Prevention in Atrial Fibrillation: David Holmes Jr, M.D., will present at
9:20 AM in the Ballroom, Level
3.
POSTER ABSTRACTS OF INTEREST
The following poster abstracts will be available for viewing on
Saturday, October 29, from
6:00 PM – 8:00
PM in Hall B, Lower Level:
- Eluvia™ Drug-Eluting Vascular Stent System: Vascular
Healing Response after Implantation of a Novel Fluoropolymer-Coated
Paclitaxel-Eluting Peripheral Stent: a Comparative Drug-Eluting
Stent Study in a Familial Hypercholesterolemic Swine Model of
Balloon-Injured Femoral Arteries: A poster by Dr. Juan Granada, M.D.
- Lotus Valve System: Four-Year Clinical Outcomes
Following TAVR with the Repositionable and Fully Retrievable Lotus
Valve System: an Update from the REPRISE I Study: A poster by
Professor Ian Meredith, M.D.
- Lotus Valve System: Predictors of Permanent Pacemaker
Implantation in Patients Treated in Routine Clinical Practice with
the Repositionable and Fully Retrievable Lotus Valve: A poster by
Dr. Nicolas Van Mieghem, M.D.,
Ph.D.
- WATCHMAN LAAC Device: Cost Effectiveness Following
Treatment Initiation of Stroke Reduction Strategies in Non-Valvular
Atrial Fibrillation: Warfarin vs NOACs vs Left Atrial Appendage
Closure: A poster by Dr. Vivek
Reddy, M.D.
- WATCHMAN LAAC Device: Do patients with CKD benefit from
Left Atrial Appendage Closure (LAAC) with WATCHMAN? Insights from
PROTECT AF: A poster by Dr. Miguel
Valderrabano, M.D.
- WATCHMAN LAAC Device: Safety and Efficacy of Left Atrial
Appendage Closure with the Watchman Device in Patients Older than
85 Years Old. Data from the Prospective EWOLUTION Registry: A
poster by Dr. Ignacio Cruz Gonzalez,
M.D.
All presentations are listed in Eastern Daylight Time and will
take place at the Walter E. Washington Convention Center. For more
information, visit Boston Scientific at booth #1525.
The company will also host an investor event and webcast at
their booth on Monday, October 31,
from 9:15 – 10:00 AM EDT to provide a
presentation and answer questions from investors about the Boston
Scientific cardiovascular portfolio. The event will be accessible
at www.bostonscientific.com/investors. A replay of the webcast will
be accessible at www.bostonscientific.com/investors beginning
approximately one hour following the completion of the event.
In the U.S., the Lotus Valve System and the Eluvia Stent System
are investigational devices and are not available for sale.
About Boston Scientific
Boston Scientific transforms
lives through innovative medical solutions that improve the health
of patients around the world. As a global medical technology
leader for more than 35 years, we advance science for life by
providing a broad range of high performance solutions that address
unmet patient needs and reduce the cost of healthcare. For more
information, visit www.bostonscientific.com and connect on Twitter
and Facebook.
CONTACTS:
Trish Backes
Media Relations
Boston Scientific Corporation
(651) 582-5887 (office)
Trish.Backes@bsci.com
Susie Lisa, CFA
Investor Relations
Boston Scientific Corporation
(508) 683-5565 (office)
investor_relations@bsci.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/boston-scientific-announces-scheduled-presentations-at-transcatheter-cardiovascular-therapeutics-2016-300349874.html
SOURCE Boston Scientific